

December 9, 2023

Monjur Ahmed, Florin Burada.

Editors-in-chief Dear Author,

Thank you for choosing to work with us again and for the positive feedback on the previous manuscript.

I have edited the manuscript to maintain the same level of quality as before. I look forward to your feedback.

World Journal of Gastrointestinal Oncology

Dear Editors,

Thank you for inviting us to submit a revised draft of our manuscript entitled **“Anti-EGFR antibody monotherapy for colorectal cancer with severe hyperbilirubinemia: A case report and review of the literature.”** in *World Journal of Gastrointestinal Oncology*. We also appreciate the time and effort you and each reviewer have dedicated to providing insightful feedback on ways to strengthen our paper.

We have incorporated changes that reflect your suggestions and added some sentences to clarify the sentence. All changes made are highlighted in yellow. Otherwise, we did not touch upon the original manuscript. A native English speaker checked the manuscript again.

To facilitate your review of our revisions, the following are point-by-point responses to your questions and comments:

Responses to the Science editor

1. INTRODUCTION section is too short.

We have supplemented the Introduction section with previous evidence and clinical problems (page 3, lines 5-11).

2. Modification of Table 1.

We have formatted Table 1 so that only three lines are displayed in accordance with to

your instructions (page 15).

Response to Reviewer 1:

1. Reduction of the Core Tip section

We deleted unnecessary sentences and retained only take-home messages. The following sentences have been deleted: “Hyperbilirubinemia with hepatic metastasis is a common but life-threatening complication of colorectal cancer. The use of cytotoxic agents for patients with hyperbilirubinemia remains controversial and an appropriate chemotherapeutic regimen has not yet been established.” (page 2, lines 23–26 in the original version).

2. Addition of HE staining figure.

We agree with your suggestion and believe that the inclusion of HE staining would make the article more convincing. However, we are concerned that it will take a long time to obtain permission to publish the pathological figures. If you still deem it necessary, then we will process the application as soon as possible; however, to do so, we will require a one-month extension to submit the revision.

3. Formatting of Figure 2 with black lines.

We have made the graphical lines black, as instructed.

4. Outcomes of each report in Table 1

We have reflected this comment by changing the column of Table 1, “Duration” (page 15). As most case reports do not address the best overall response or cause of discontinuation, we inserted a column for overall survival after the initiation of panitumumab-containing chemotherapy.

Response to Reviewer 2:

Thank you for this comment.

Lastly, according to the format, we have added *History of present illness*, *History of past illness* and *Personal and family history* sections (page 3, line 22 – page 4, line 2).

Thank you again for giving us the opportunity to strengthen our manuscript based on

your valuable comments and queries. We have worked hard to incorporate your feedback and hope that these revisions have persuaded you to accept our submission.

Sincerely,

Toshiaki Tsurui

Division of Medical Oncology, Department of Medicine, School of Medicine, Showa University

1-5-8 Hatanodai, Shinagawa-ku, Tokyo 1428555, Japan

+81-3-3784-8000

ttsurui.quantum@gmail.com